

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia https://doi.org/10.1007/s00125-018-4772-2.

Manuscript DOI: https://doi.org/10.2337/DB21-1010 (Example, https://doi.org/10.2337/db18-1234)

Title: RhoA as a signaling hub controlling glucagon secretion from pancreatic α-cells

Author list: Xue Wen Ng*, Yong Hee Chung*, Farzad Asadi, Chen Kong, Alessandro Ustione, David W. Piston

Corresponding author: David W. Piston

Email address: piston@wustl.edu

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	DON253	DON304	DON315					
Donor age (years)	13	19	10					
Donor sex (M/F)	F	М	М					
Donor BMI (kg/m²)	17.9	25.3	16.5					

Donor HbA _{1c} or other measure of blood glucose control	12.8	10.9	9.7					
Origin/source of islets ^b	nPOD	nPOD	nPOD					
Islet isolation centre	University of Pittsburgh	University of Pittsburgh	University of Pittsburgh					
Donor history of diabetes? Yes/No	Yes	Yes	Yes					
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)	6	8	7					
Glucose-lowering therapy at time of death ^c	Insulin	Insulin	Insulin					

RECOMMENDED INFORMATION								
Donor cause of death	DBD	DBD	Not indicated					
Warm ischaemia time (h)								
Cold ischaemia time (h)	11.3	16	17					

Estimated purity (%)		20-25%	20-25%			
Estimated viability (%)						
Total culture time (h)d	17	95.5	44			
Glucose-stimulated insulin secretion or other functional measuremente						
Handpicked to purity? Yes/No						
Additional notes						

^aIf you have used more than eight islet preparations, please complete additional forms as necessary ^bFor example, IIDP, ECIT, Alberta IsletCore ^cPlease specify the therapy/therapies ^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory ^ePlease specify the test and the results